Alazocine
 | |
| Clinical data | |
|---|---|
| Routes of administration | ? |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| ChEMBL | |
| ECHA InfoCard | 100.162.264 |
| Chemical and physical data | |
| Formula | C17H23NO |
| Molar mass | 257.37 g/mol |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Alazocine ((-)-SKF-10,047), or (-)-N-allylnormetazocine ((-)-ANMC), was the first drug discovered to act as a σ1 receptor agonist (Ki = 24 nM).[1][2][3] It has no significant affinity for the σ2 receptor.[3] Alazocine also acts as a κ-opioid receptor partial agonist (Ki = 0.4 nM; EC50 = 24 nM; Emax = 66%),[4] and to a much lesser extent, as an NMDA receptor antagonist (Ki = 587 nM).[3][5]
See also
References
- ↑ Iwamoto ET (February 1981). "Pharmacologic effects of N-allylnormetazocine (SKF-10047)". NIDA Research Monograph. 34: 82–8. PMID 6783955.
- ↑ Shearman GT, Herz A (August 1982). "Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat". European Journal of Pharmacology. 82 (3–4): 167–72. PMID 6290235. doi:10.1016/0014-2999(82)90506-4.
- 1 2 3 Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (March 1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research. 821 (2): 516–9. PMID 10064839. doi:10.1016/S0006-8993(99)01125-7.
- ↑ Gharagozlou, Parham; Hashemi, Ezzat; DeLorey, TimothyM; Clark, J David; Lameh, Jelveh (2006). "Pharmacological profiles of opioid ligands at Kappa opioid receptors". BMC Pharmacology. 6 (1): 3. ISSN 1471-2210. PMC 1403760
. PMID 16433932. doi:10.1186/1471-2210-6-3. - ↑ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J (2006). "Pharmacological profiles of opioid ligands at Kappa opioid receptors". BMC Pharmacology. 6 (1): 3. PMC 1403760 . PMID 16433932. doi:10.1186/1471-2210-6-3.
| Receptor (ligands) |
| ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (blockers) |
| ||||||||||||||||||||||||||
| Enzyme (inhibitors) |
| ||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||
See also: Receptor/signaling modulators • GABAergics • GHBergics • Glycinergics | |||||||||||||||||||||||||||
| MOR |
|
|---|---|
| DOR |
|
| KOR |
|
| NOP |
|
| Unsorted |
|
| Others |
|
See also: Receptor/signaling modulators • Signaling peptide/protein receptor modulators | |
| σR |
|
|---|---|
See also: Receptor/signaling modulators | |
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.